Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Feb;47:322–329.

Delivery systems for acute migraine medications.

I Worthington 1
PMCID: PMC2016250  PMID: 11228033

Abstract

OBJECTIVE: To discuss advantages and disadvantages of various routes of administration and delivery systems for acute migraine medications, and to assist family physicians in optimizing treatment for individual patients. QUALITY OF EVIDENCE: A MEDLINE search from January 1966 to October 2000 and a Current Contents search for the year 1999 to October 2000 were conducted. Randomized controlled trials were selected, when available. Also included are guidelines (Canadian), non-blinded trials, systematic reviews, and population-based studies. MAIN MESSAGE: Selecting an appropriate way to deliver medication is important in acute migraine therapy. The parenteral route has advantages, such as rapid onset, greater efficacy, and the possibility of use during nausea and vomiting. Disadvantages include local site discomfort, inconvenience, and patients' dislike of needles. Most patients prefer oral therapy, but gastric stasis and nausea and vomiting during a migraine attack might limit its use. The intranasal route usually provides fairly rapid onset, but side effects, such as disturbances in taste, can occur. The rectal route is another option, but absorption is sometimes erratic, rectal irritation can occur, and few migraine medications are available in rectal formulation. CONCLUSION: Selection of appropriate medications and suitable delivery systems for individual patients, based on the characteristics of their attacks (e.g., severity, speed of progression to severe intensity, degree of associated symptoms), ease of administration, and patient preference, will optimize therapy for acute migraine attacks.

Full Text

The Full Text of this article is available as a PDF (61.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman J. U., Mannix L. K., Von Seggern R. L. Rizatriptan tablet versus wafer: patient preference. Headache. 2000 May;40(5):371–372. doi: 10.1046/j.1526-4610.2000.00055.x. [DOI] [PubMed] [Google Scholar]
  2. Ahrens S. P., Farmer M. V., Williams D. L., Willoughby E., Jiang K., Block G. A., Visser W. H. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999 Jun;19(5):525–530. doi: 10.1046/j.1468-2982.1999.019005525.x. [DOI] [PubMed] [Google Scholar]
  3. Ashford E., Salonen R., Saiers J., Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia. 1998 Jun;18(5):273–277. doi: 10.1046/j.1468-2982.1998.1805273.x. [DOI] [PubMed] [Google Scholar]
  4. Becker W. J., Riess C. M., Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996 Mar;36(3):144–148. doi: 10.1046/j.1526-4610.1996.3603144.x. [DOI] [PubMed] [Google Scholar]
  5. Cady R. C., Ryan R., Jhingran P., O'Quinn S., Pait D. G. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998 May 11;158(9):1013–1018. doi: 10.1001/archinte.158.9.1013. [DOI] [PubMed] [Google Scholar]
  6. Dahlof CG, Solomon GD. The burden of migraine to the individual sufferer: a review. Eur J Neurol. 1998 Nov;5(6):525–533. doi: 10.1046/j.1468-1331.1998.560525.x. [DOI] [PubMed] [Google Scholar]
  7. Dahlöf C. G., Boes-Hansen S., Cederberg C. G., Hardebo J. E., Henriksson A. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia. 1998 Jun;18(5):278–282. doi: 10.1046/j.1468-2982.1998.1805278.x. [DOI] [PubMed] [Google Scholar]
  8. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia. 1993 Jun;13(3):166–171. doi: 10.1046/j.1468-2982.1993.1303166.x. [DOI] [PubMed] [Google Scholar]
  9. Diamond S., Elkind A., Jackson R. T., Ryan R., DeBussey S., Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med. 1998 May-Jun;7(3):234–240. doi: 10.1001/archfami.7.3.234. [DOI] [PubMed] [Google Scholar]
  10. Edmeads J., Findlay H., Tugwell P., Pryse-Phillips W., Nelson R. F., Murray T. J. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci. 1993 May;20(2):131–137. doi: 10.1017/s0317167100047697. [DOI] [PubMed] [Google Scholar]
  11. Gruffydd-Jones K., Hood C. A., Price D. B. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia. 1997 Feb;17(1):31–36. doi: 10.1046/j.1468-2982.1997.1701031.x. [DOI] [PubMed] [Google Scholar]
  12. Hoffert M. J., Couch J. R., Diamond S., Elkind A. H., Goldstein J., Kohlerman N. J., 3rd, Saper J. R., Solomon S. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995 Feb;35(2):65–69. doi: 10.1111/j.1526-4610.1995.hed3502065.x. [DOI] [PubMed] [Google Scholar]
  13. Jones E. B., Gonzalez E. R., Boggs J. G., Grillo J. A., Elswick R. K., Jr Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994 Aug;24(2):237–241. doi: 10.1016/s0196-0644(94)70135-0. [DOI] [PubMed] [Google Scholar]
  14. Kellstein D. E., Lipton R. B., Geetha R., Koronkiewicz K., Evans F. T., Stewart W. F., Wilkes K., Furey S. A., Subramanian T., Cooper S. A. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000 May;20(4):233–243. doi: 10.1046/j.1468-2982.2000.00055.x. [DOI] [PubMed] [Google Scholar]
  15. Klapper J. A., Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992 Jan;32(1):21–23. doi: 10.1111/j.1526-4610.1992.hed3201021.x. [DOI] [PubMed] [Google Scholar]
  16. Kramer M. S., Matzura-Wolfe D., Polis A., Getson A., Amaraneni P. G., Solbach M. P., McHugh W., Feighner J., Silberstein S., Reines S. A. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998 Sep;51(3):773–781. doi: 10.1212/wnl.51.3.773. [DOI] [PubMed] [Google Scholar]
  17. Kunka R. L., Hussey E. K., Shaw S., Warner P., Aubert B., Richard I., Fowler P. A., Pakes G. E. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia. 1997 Jun;17(4):532–540. doi: 10.1046/j.1468-2982.1997.1704532.x. [DOI] [PubMed] [Google Scholar]
  18. Lavin P. Subacute angle-closure glaucoma as a cause of headache. Headache. 1999 Jul-Aug;39(7):520–521. [PubMed] [Google Scholar]
  19. MacGregor E. A., Wilkinson M., Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993 Apr;13(2):124–127. doi: 10.1046/j.1468-2982.1993.1302124.x. [DOI] [PubMed] [Google Scholar]
  20. Maizels M., Scott B., Cohen W., Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA. 1996 Jul 24;276(4):319–321. [PubMed] [Google Scholar]
  21. Newman L. C., Lipton R. B., Russell M., Solomon S. Hemicrania continua: attacks may alternate sides. Headache. 1992 May;32(5):237–238. doi: 10.1111/j.1526-4610.1992.hed3205237.x. [DOI] [PubMed] [Google Scholar]
  22. Peatfield R. C. Migraine: which triptan? Hosp Med. 1999 Apr;60(4):277–280. doi: 10.12968/hosp.1999.60.4.1095. [DOI] [PubMed] [Google Scholar]
  23. Pryse-Phillips W. E., Dodick D. W., Edmeads J. G., Gawel M. J., Nelson R. F., Purdy R. A., Robinson G., Stirling D., Worthington I. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1997 May 1;156(9):1273–1287. [PMC free article] [PubMed] [Google Scholar]
  24. Pryse-Phillips W. E., Dodick D. W., Edmeads J. G., Gawel M. J., Nelson R. F., Purdy R. A., Robinson G., Stirling D., Worthington I. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1998 Jul 14;159(1):47–54. [PMC free article] [PubMed] [Google Scholar]
  25. Sawynok J., Yaksh T. L. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev. 1993 Mar;45(1):43–85. [PubMed] [Google Scholar]
  26. Stewart W. F., Shechter A., Rasmussen B. K. Migraine prevalence. A review of population-based studies. Neurology. 1994 Jun;44(6 Suppl 4):S17–S23. [PubMed] [Google Scholar]
  27. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia. 1998 Oct;18(8):532–538. doi: 10.1046/j.1468-2982.1998.1808532.x. [DOI] [PubMed] [Google Scholar]
  28. Thomsen L. L., Dixon R., Lassen L. H., Gibbens M., Langemark M., Bendtsen L., Daugaard D., Olesen J. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996 Jun;16(4):270–275. doi: 10.1046/j.1468-2982.1996.1604270.x. [DOI] [PubMed] [Google Scholar]
  29. Weisz M. A., el-Raheb M., Blumenthal H. J. Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache. 1994 Jun;34(6):371–373. doi: 10.1111/j.1526-4610.1994.hed3406371.x. [DOI] [PubMed] [Google Scholar]
  30. de Lissovoy G., Lazarus S. S. The economic cost of migraine. Present state of knowledge. Neurology. 1994 Jun;44(6 Suppl 4):S56–S62. [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES